keyword
MENU ▼
Read by QxMD icon Read
search

Esomeprazole

keyword
https://www.readbyqxmd.com/read/29758543/magnesium-sulfate-versus-esomeprazole-impact-on-the-neonates-of-preeclamptic-rats
#1
Amani N Shafik, Mahmoud A Khattab, Ahmed H Osman
OBJECTIVE: Preeclampsia represents a major complication of pregnancy, associated with greater maternal and fetal complications. We compared the effects of esomeprazole (a proton pump inhibitor) and magnesium sulfate (MgSO4) on the deleterious effects observed on the mother and neonates in experimentally induced preeclampsia in rats. STUDY DESIGN: Preeclampsia was induced in pregnant rats with NG-nitro-l-arginine methyl ester (L-NAME) starting from day 10-till end of pregnancy...
May 8, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29722146/prevention-of-post-sphincterotomy-bleeding-by-proton-pump-inhibitor-a-randomized-controlled-trial
#2
Wai K Leung, David Yk But, S Y Wong, Teresa Sm Tong, Kevin Sh Liu, Ka-Shing Cheung, Simon Hy Tsang, Kenneth Sh Chok, Ronnie Tp Poon, Ivan Fn Hung
AIM: Post-sphincterotomy (EST) bleeding is one of the most frequent complications of endoscopic retrograde cholangiopancreatography (ERCP). Although the use of proton pump inhibitor (PPI) has been shown to reduce the risk of peptic ulcer bleeding, the role of PPI in preventing EST bleeding has not been evaluated. This study determined the role of pre-emptive PPI in patients undergoing EST. METHODS: It was an investigator-initiated open-label randomized study. Consecutive patients who were scheduled to have ERCP and EST were enrolled...
May 2, 2018: Journal of Digestive Diseases
https://www.readbyqxmd.com/read/29696736/bismuth-improves-efficacy-of-proton-pump-inhibitor-clarithromycin-metronidazole-triple-helicobacter-pylori-therapy-despite-a-high-prevalence-of-antimicrobial-resistance
#3
Xiaohua Long, Qi Chen, Lou Yu, Xiao Liang, Wenzhong Liu, Hong Lu
BACKGROUND: Helicobacter pylori (H. pylori) eradication has become increasingly difficult especially for penicillin allergy patients. AIMS: To evaluate the efficacy of adding bismuth or high-dose metronidazole to an H. pylori eradication regimen containing a proton-pump inhibitor, clarithromycin, and metronidazole in patients allergic to penicillin. METHODS: Pilot study in which penicillin-allergic, treatment-naive subjects were randomized (1:1) to 14-day esomeprazole (20 mg q12h), clarithromycin (500 mg q12h), and high dose of metronidazole (400 mg q6h) with (BECM group) or without (ECM group) bismuth (600 mg q12h)...
April 25, 2018: Helicobacter
https://www.readbyqxmd.com/read/29688583/safe-use-of-proton-pump-inhibitors-in-patients-with-cirrhosis
#4
Rianne A Weersink, Margriet Bouma, David M Burger, Joost P H Drenth, S Froukje Harkes-Idzinga, Nicole G M Hunfeld, Herold J Metselaar, Margje H Monster-Simons, Sandra A W van Putten, Katja Taxis, Sander D Borgsteede
AIMS: Proton pump inhibitors (PPIs) belong to the most frequently used drugs, also in patients with cirrhosis. PPIs are extensively metabolized by the liver, but practice guidance on prescribing in cirrhosis is lacking. We aim to develop practical guidance on the safe use of PPIs in cirrhosis. METHODS: A systematic literature search identified studies about the safety (i.e. adverse events) and pharmacokinetics of PPIs in cirrhotic patients. This evidence and data from the product information was reviewed by an expert panel who classified drugs as safe; no additional risks known; additional risks known; unsafe; or unknown...
April 24, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29688503/the-potential-benefits-of-aspirin-for-primary-cardiovascular-prevention-in-rheumatoid-arthritis-a-secondary-analysis-of-the-precision-trial
#5
Daniel H Solomon, Peter Libby, Neville D Yeomans, Qiuqing Wang, Kathy E Wolski, Steven E Nissen, M Elaine Husni
Objective: Guidelines exist for the use of low-dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit considerations may differ in RA. While RA confers an increased CV risk, such patients more likely use NSAIDs and corticosteroids. Methods: We conducted a cohort study to assess potential risks and benefits of low-dose aspirin. We estimated incidence rates and hazard ratios (HRs) using Cox regression among subjects with RA but no known CV disease in the Prospective Randomized Evaluation of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen trial...
April 20, 2018: Rheumatology
https://www.readbyqxmd.com/read/29670650/effects-of-vonoprazan-compared-with-esomeprazole-on-the-healing-of-artificial-postendoscopic-submucosal-dissection-ulcers-a-prospective-multicenter-two-arm-randomized-controlled-trial
#6
Yasuaki Ishii, Hiroaki Yamada, Takeshi Sato, Soichiro Sue, Hiroaki Kaneko, Kuniyasu Irie, Tomohiko Sasaki, Toshihide Tamura, Ryosuke Ikeda, Takehide Fukuchi, Ryosuke Kobayashi, Makomo Makazu, Chiko Sato, Kingo Hirasawa, Masaaki Kondo, Wataru Shibata, Shin Maeda
Background: Vonoprazan affords more clinical benefits than proton pump inhibitors (PPIs) during the healing of gastroduodenal ulcers. However, it remains controversial whether vonoprazan is more effective than PPIs when used to heal artificial ulcers arising after endoscopic submucosal dissection (ESD). Aim: This study investigated the effects of vonoprazan compared with esomeprazole on the healing of post-ESD artificial ulcers. Methods: Sixty patients who underwent gastric ESD between May 2015 and May 2017 were randomized to treatment with vonoprazan (V group) or esomeprazole (E group) for 8 weeks...
2018: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29669354/effectiveness-and-safety-of-pylera%C3%A2-in-patients-infected-by-helicobacter-pylori-a-multicenter-retrospective-real-life-study
#7
Antonio Tursi, Marilisa Franceschi, Leonardo Allegretta, Edoardo Savarino, Rudi De Bastiani, Walter Elisei, Gianluca Baldassarre, Antonio Ferronato, Serena Scida, Chiara Miraglia, Antonio Penna, Claudio Licci, Giovanni Luca Rizzo, Giuseppe Pranzo, Claudio Cassieri, Giovanni Brandimarte, Marcello Picchio, Francesco Di Mario
BACKGROUND: Our aims were to assess the real life effectiveness and safety of the new bismuth-containing quadruple therapy in a large population of patients infected by Helicobacter pylori. METHODS: Consecutive dyspeptic H. pylori-positive patients were enrolled, both naïve for treatment and already unsuccessfully treated. Patients were treated with Pylera® 3 capsules 4 times/daily plus omeprazole 20 mg or esomeprazole 40 mg 2 times/daily for 10 days. Eradication was confirmed using a urea-breath test (at least 30 days after the end of the treatment)...
April 17, 2018: Digestive Diseases
https://www.readbyqxmd.com/read/29667211/randomised-clinical-trial-gastrointestinal-events-in-arthritis-patients-treated-with-celecoxib-ibuprofen-or-naproxen-in-the-precision-trial
#8
N D Yeomans, D Y Graham, M E Husni, D H Solomon, T Stevens, J Vargo, Q Wang, L M Wisniewski, K E Wolski, J S Borer, P Libby, A M Lincoff, T F Lüscher, W Bao, C Walker, S E Nissen
BACKGROUND: We evaluated GI safety of celecoxib compared with 2 nonselective (ns) NSAIDs, as a secondary objective of a large trial examining multiorgan safety. METHODS: This randomised, double-blind controlled trial analysed 24 081 patients. Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b.d., ibuprofen 600-800 mg t.d.s. or naproxen 375-500 mg b.d. plus esomeprazole, and low-dose aspirin or corticosteroids if already prescribed...
April 17, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29609611/association-between-industry-payments-and-prescribing-costly-medications-an-observational-study-using-open-payments-and-medicare-part-d-data
#9
Manvi Sharma, Aisha Vadhariya, Michael L Johnson, Zachary A Marcum, Holly M Holmes
BACKGROUND: While many new medications may offer advantages over existing drugs, some newer drugs are reformulations of existing products that provide little innovation or incremental benefit while driving up drug costs. Despite the lack of benefit of these medications, prescribers may be motivated by payments made by the pharmaceutical industry. The objective of the study was to determine the association between payments made to physicians by the pharmaceutical industry and prescriptions for certain selected costly brand name drugs...
April 2, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29575167/empirical-treatment-of-outpatients-with-gastroesophageal-reflux-disease-with-proton-pump-inhibitors-a-survey-of-chinese-patients-the-enlight-study
#10
Bin Lu, Ling Zhang, Jiangbin Wang, Bangmao Wang, Xiaoping Zou, Guijun Fei, Dongfeng Chen, Xuehong Wang, Bin Wu, Duowu Zou
BACKGROUND: Empirical proton pump inhibitor (PPI) treatment is recommended as a diagnostic indicator for GERD and as a therapy for symptomatic control, with responses generally seen within 4 weeks. However, there are no real-world data assessing the effectiveness of short-term empirical treatment with PPIs in patients with GERD in China. METHODS: The ENLIGHT study was a multicenter, prospective, observational study conducted in China. The primary outcome was the overall response rate after 4 weeks' empirical treatment with PPIs...
March 25, 2018: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29554952/in-vitro-comparative-quality-evaluation-of-different-brands-of-esomeprazole-tablets-available-in-selected-community-pharmacies-in-dhaka-bangladesh
#11
Oby Dulla, Sharifa Sultana, Md Shohag Hosen
OBJECTIVE: Esomeprazole is the S-isomer of omeprazole, used to treat gastro esophageal reflux disease. It is one of the widely manufactured and marketed drugs by many pharmaceutical companies in Bangladesh. The aim of the study is to compare the different physical parameters including hardness, friability, diameter, thickness, disintegration time, dissolution test and assay for quality evaluation and characterization of tablets of five different brands of Bangladeshi pharmaceutical company...
March 20, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29540336/a-randomized-double-blind-controlled-multi-center-study-of-ilaparazole-in-the-treatment-of-reflux-esophagitis-phase-iii-clinical-trial
#12
Yan Xue, Xianghong Qin, Liya Zhou, Sanren Lin, Ling Wang, Haitang Hu, Jielai Xia
AIM AND BACKGROUND: Proton pump inhibitors (PPIs) are the main drugs for the treatment of reflux esophagitis. Phase II clinical trials showed that, compared with Esomeprazole, the new PPI Ilaparazole is great in terms of efficacy for reflux symptoms relief and curling for esophagitis. The aim of this study was to confirm suitable dose of Ilaparazole in the treatment of reflux esophagitis. METHODS: This study used a randomized, double-blind, parallel positive drug control, multi-center design...
March 11, 2018: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29526982/-rhabdomyolysis-associated-with-long-term-treatment-of-esomeprazole
#13
Jun Nishikawa, Ayumu Hosokawa, Mayo Fuchino, Shunsuke Takatori, Masaya Iwamoto, Yoshiro Kashii, Tadashi Bando, Tetsuro Shimizu, Masami Minemura, Toshiro Sugiyama
Proton pump inhibitors (PPIs) have been widely used in the treatment of gastroesophageal reflux disease and peptic ulcer disease. Although they have a potent acid suppressive effect and excellent efficacy in acid-related diseases, PPI-induced rhabdomyolysis has been reported. Here, we report the case of a patient with reflux esophagitis who developed rhabdomyolysis after esomeprazole treatment. A 67-year-old man with reflux esophagitis who had started esomeprazole treatment for the preceding 10 months complained of back and limb fatigue and myalgia...
2018: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://www.readbyqxmd.com/read/29509636/long-term-treatment-with-proton-pump-inhibitors-is-effective-in-children-with-eosinophilic-esophagitis
#14
Carolina Gutiérrez-Junquera, Sonia Fernández-Fernández, M Luz Cilleruelo, Ana Rayo, Luis Echeverría, Belén Borrell, Enriqueta Román
OBJECTIVES: Proton pump inhibitor (PPI)-responsive eosinophilic esophagitis (EoE) is frequently observed in children, but data on long-term treatment are scarce. The objective of this study is to evaluate the long-term efficacy and safety of PPIs in children with EoE. METHODS: This prospective study enrolled children with EoE and histological remission to an 8-week esomeprazole trial (1 mg/kg/dose, twice daily). Esomeprazole was maintained at 1 mg/kg/day for 1 year...
March 5, 2018: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29507467/hybrid-therapy-as-first-line-regimen-for-helicobacter-pylori-eradication-in-a-high-clarithromycin-resistance-area-a-prospective-open-label-trial
#15
Sotirios D Georgopoulos, Vasilios Papastergiou, Beatriz Martinez-Gonzalez, Elias Xirouchakis, Ioannis Familias, Dionysis Sgouras, Andreas Mentis, Stylianos Karatapanis
Background: Hybrid therapy is a promising first-line regimen for Helicobacter pylori ( H. pylori ) eradication. We evaluated a hybrid therapy, assessing the impact of antibiotic resistance on eradication outcome. Methods: This was a prospective study that included 155 treatment-naïve patients diagnosed with H. pylori infection by positive CLO-test, confirmed with histology and/or culture. The hybrid therapy consisted of 40 mg esomeprazole and 1 g amoxicillin for 14 days, with the addition of 500 mg clarithromycin and 500 mg metronidazole for the final 7 days (all b...
March 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29507466/seven-day-genotypic-resistance-guided-triple-helicobacter-pylori-eradication-therapy-can-be-highly-effective
#16
Vasilios Papastergiou, Nicoletta Mathou, Sophia Licousi, Aikaterini Evgenidi, Konstantina D Paraskeva, Athanasios Giannakopoulos, Pinelopi-Zoi Stavrou, Evangelia Platsouka, John A Karagiannis
Background: The efficacy and applicability of molecular testing to guide the selection of antibiotics in triple Helicobacter pylori ( H. pylori) eradication regimens have not been reported. We tested a 7-day, genotypic resistance-guided triple H. pylori eradication therapy in a high-resistance setting. Methods: Consecutive dyspeptic patients with H. pylori infection were prospectively enrolled. Genotypic resistances to clarithromycin ( 23SrRNA mutations) and fluoroquinolones ( gyrA mutations) were determined from gastric biopsy specimens using a commercially available molecular assay (GenoTypeâ HelicoDR)...
March 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29504209/brief-report-lactobacillus-bulgaricus-glb44-proviotic-%C3%A2-plus-esomeprazole-for-helicobacter-pylori-eradication-a-pilot-study
#17
Antone R Opekun, Savannah A Gonzales, Mahmoud A Al-Saadi, David Y Graham
BACKGROUND: Recent studies of Lactobacillus delbrueckii subsp. bulgaricus GLB44 plus a proton-pump inhibitor (PPI) reported cures of more than 90% of patients with active Helicobacter pylori infections. AIM: To confirm the high H. pylori cure rates reported previously. METHOD: A pilot study was done in healthy H. pylori-infected volunteers using 3-gram sachet (3 billion cells) of L. delbrueckii GLB44 plus 22.3 mg of esomeprazole b.i.d...
April 2018: Helicobacter
https://www.readbyqxmd.com/read/29487220/effect-of-concomitant-ph-elevating-medications-with-pazopanib-on-progression-free-survival-and-overall-survival-in-patients-with-metastatic-renal-cell-carcinoma
#18
Renee K McAlister, Jonathan Aston, Megan Pollack, Liping Du, Tatsuki Koyama, David D Chism
BACKGROUND: Pazopanib is an oral tyrosine-kinase inhibitor that is approved by the U.S. Food and Drug Administration for treatment of metastatic renal cell carcinoma (mRCC). Pharmacokinetic data have shown that concomitant administration of pazopanib and esomeprazole, a proton pump inhibitor (PPI), leads to decreased area under the curve and thus decreased exposure of pazopanib by 40%. Despite the pharmacokinetic data published to date, the clinical significance and impact on patient outcomes resulting from decreased pazopanib exposure remains unknown...
February 27, 2018: Oncologist
https://www.readbyqxmd.com/read/29481383/pylera-and-sequential-therapy-for-first-line-helicobacter-pylori-eradication-a-culture-based-study-in-real-clinical-practice
#19
Giulia Fiorini, Angelo Zullo, Ilaria M Saracino, Luigi Gatta, Matteo Pavoni, Dino Vaira
BACKGROUND AND AIMS: Italian guideline suggests 10-day sequential or bismuth-based quadruple therapies for first-line Helicobacter pylori treatment. Comparison between these regimens is lacking. We assessed the efficacy of these therapies in clinical practice and evaluated the role of primary bacterial resistance toward clarithromycin and metronidazole. PATIENTS AND METHODS: Consecutive patients with H. pylori infection were enrolled. Bacterial culture with antibiotics susceptibility testing was attempted in all cases...
June 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29466360/combining-metformin-and-esomeprazole-is-additive-in-reducing-sflt-1-secretion-and-decreasing-endothelial-dysfunction-implications-for-treating-preeclampsia
#20
Tu'uhevaha J Kaitu'u-Lino, Fiona C Brownfoot, Sally Beard, Ping Cannon, Roxanne Hastie, Tuong V Nguyen, Natalie K Binder, Stephen Tong, Natalie J Hannan
INTRODUCTION: The discovery of new treatments that prevent or treat preeclampsia would be a major advance. Antiangiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG) are secreted in excess from the placenta, causing hypertension, endothelial dysfunction, and multiorgan injury. We recently identified metformin and esomeprazole as potential treatments for preeclampsia. Both reduce placental and endothelial secretion of sFlt-1 and soluble endoglin, and reduce endothelial dysfunction...
2018: PloS One
keyword
keyword
3616
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"